Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study.
Kahraman S, Hizal M, Demirel BC, Guven DC, Gumusay O, Uluc BO, Bayram E, Gulbagci B, Yasar A, Davarci SE, Mocan EE, Acar O, Isik D, Aydin E, Karakas Y, Ozcelik M, Keser M, Okutur SK, Eren O, Menekse S, Aydin D, Yilmaz F, Dogan O, Ozkanli G, Yucel H, Sunar V, Aykan MB, Ozdemir O, Duman BB, Keskinkilic M, Sakalar T, Inal A, Karaoglanoglu M, Aksoy A, Er MM, Turhal NS, Kalkan NO, Sendur MAN. Kahraman S, et al. Among authors: keskinkilic m. BMC Cancer. 2024 Dec 30;24(1):1592. doi: 10.1186/s12885-024-13357-5. BMC Cancer. 2024. PMID: 39736618 Free PMC article.
Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study.
Ön S, Köksal B, Arık Z, Caner B, Ercan Uzundal D, Yazıcı O, Arslan Benli B, Eylemer Mocan E, Güngör C, Güç ZG, Akay S, Keskinkılıç M, Dik Avcı H, Karaca Yayla B, Çakar B, Şanlı UA. Ön S, et al. Among authors: keskinkilic m. Curr Oncol. 2024 Nov 1;31(11):6803-6813. doi: 10.3390/curroncol31110502. Curr Oncol. 2024. PMID: 39590133 Free PMC article.
The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials.
Keskinkilic M, Arayici ME, Basbinar Y, Ellidokuz H, Yavuzsen T, Oztop I. Keskinkilic M, et al. Breast. 2024 Dec;78:103815. doi: 10.1016/j.breast.2024.103815. Epub 2024 Oct 15. Breast. 2024. PMID: 39413680 Free article.
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Özyurt N, Alkan A, Gülbağcı B, Seyyar M, Aydın E, Şahbazlar M, Türker M, Kınıkoğlu O, Yerlikaya T, Dinç G, Aytaç A, Kalkan Z, Ebinç S, Gültürk İ, Keskinkılıç M, İşleyen ZS, Çağlayan D, Türkel A, Aydın E, Şakalar T, Sekmek S, Yıldırım N, Koçak S, Okutur K, Özveren A, Dursun B, Kitaplı S, Eren OÖ, Beypınar İ, Hacıbekiroğlu İ, Çabuk D, Karaman E, Acar Ö, Paydaş S, Eryılmaz MK, Demir B, Oruç Z, Yılmaz M, Biricik FS, Salim DK, Tanrıverdi Ö, Doğan M. Özyurt N, et al. Among authors: keskinkilic m. Sci Rep. 2024 Oct 9;14(1):23556. doi: 10.1038/s41598-024-75293-5. Sci Rep. 2024. PMID: 39384975 Free PMC article.
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.
Beypınar İ, Demir H, Yaslıkaya Ş, Köşeci T, Demir B, Çolak G, Ağaoğlu AB, Şahbazlar M, Şancı PC, Çabuk D, Işık U, Şahin E, Coşkun A, Caner B, Aykut T, Artaç M, Duygulu ME, Sever N, Öksüz S, Turan N, Aykan MB, Tüzün EK, Uysal M, Uğurlu İ, Sakin A, Acar C, Özaşkın D, Şakalar T, Keskinkılıç M, Yavuzşen T, Köse N, Ertürk İ, Yıldırım N, Balçık OY, Alkan A, Selvi O, Erçin E, Ünal OÜ, Karaçin C. Beypınar İ, et al. Among authors: keskinkilic m. Breast Cancer Res Treat. 2024 Dec;208(3):597-604. doi: 10.1007/s10549-024-07456-x. Epub 2024 Aug 9. Breast Cancer Res Treat. 2024. PMID: 39123071
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.
Yildirim HC, Kapar C, Koksal B, Seyyar M, Sanci PC, Guliyev M, Perkin P, Buyukkor M, Yaslikaya S, Majidova N, Keskinkilic M, Ozaskin D, Avci T, Gunes TK, Arcagok M, Topal A, Keskin GSY, Kavgaci G, Yildirim N, Celayir OM, Avci N, Aslan F, Alkan A, Erciyestepe M, Cengiz M, Pehlivan M, Gulmez A, Beypinar I, Basoglu Tuylu T, Kayikcioglu E, Chalabiyev E, Turhal S, Guzel HG, Ayas E, Sahbazlar M, Dulgar O, Demir H, Yavuzsen T, Bayoglu V, Kivrak Salim D, Ozturk B, Ozdemir F, Kara O, Oksuzoglu B, Bal O, Demirci NS, Yilmaz M, Cabuk D, Aksoy S. Yildirim HC, et al. Among authors: keskinkilic m. J Chemother. 2024 Mar 18:1-7. doi: 10.1080/1120009X.2024.2330835. Online ahead of print. J Chemother. 2024. PMID: 38497444
25 results